Search hospitals > Texas > Tyler
Tyler Research Institute, LLC
Claim this profileTyler, Texas 75701
Global Leader in Ulcerative Colitis
Global Leader in Inflammatory Bowel Disease
Conducts research for Ulcer
Conducts research for Crohn's Disease
Conducts research for Esophagitis
47 reported clinical trials
2 medical researchers
Summary
Tyler Research Institute, LLC is a medical facility located in Tyler, Texas. This center is recognized for care of Ulcerative Colitis, Inflammatory Bowel Disease, Ulcer, Crohn's Disease, Esophagitis and other specialties. Tyler Research Institute, LLC is involved with conducting 47 clinical trials across 7 conditions. There are 2 research doctors associated with this hospital, such as George Aaron DuVall and George DuVall.Top PIs
George Aaron DuVallTyler Research Institute, LLC5 years of reported clinical research
Studies Ulcerative Colitis
Studies Inflammatory Bowel Disease
8 reported clinical trials
7 drugs studied
George DuVallTyler Research Institute, LLC5 years of reported clinical research
Studies Crohn's Disease
Studies Esophagitis
6 reported clinical trials
5 drugs studied
Clinical Trials running at Tyler Research Institute, LLC
Ulcerative Colitis
Crohn's Disease
Ulcer
Inflammatory Bowel Disease
Esophagitis
Eosinophilic Esophagitis
Ozanimod
for Ulcerative Colitis
The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
Recruiting4 awards Phase 4
Vedolizumab + Tofacitinib
for Ulcerative Colitis
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks. Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.
Recruiting3 awards Phase 47 criteria
ABX464 Maintenance Therapy
for Ulcerative Colitis
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106. All eligible subjects who have completed either one of the induction studies above mentioned, will be given the opportunity to take part in the present ABX464-107 maintenance study and will be randomized to either a double blind, placebo-controlled part (Part #1) or allocated to ABX464 50mg or 25mg open label treatment arms (Part #2) depending on their clinical response at the end of induction. This study consists of a 44-week treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit.
Recruiting1 award Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Tyler Research Institute, LLC?
Tyler Research Institute, LLC is a medical facility located in Tyler, Texas. This center is recognized for care of Ulcerative Colitis, Inflammatory Bowel Disease, Ulcer, Crohn's Disease, Esophagitis and other specialties. Tyler Research Institute, LLC is involved with conducting 47 clinical trials across 7 conditions. There are 2 research doctors associated with this hospital, such as George Aaron DuVall and George DuVall.